Medical Management of Diabetic Foot Infections

References

• . Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217–228
   PubMed Web of Science ®Google Scholar
• . Boulton AJ, Vileikyte L, Ragnarson—Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719–1724
   PubMed Web of Science ®Google Scholar
• . Iversen MM, Tell GS, Riise T, . History of foot ulcer increases mortality among individuals with diabetes: ten-year follow-up of the Nord-Trøndelag Health Study, Norway. Diabetes Care. 2009;32(12):2193–2199
   PubMed Web of Science ®Google Scholar
• . Lavery LA, Armstrong DG, Wunderlich R P, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006;29(6):1288–1293
   PubMed Web of Science ®Google Scholar
• . Prompers L, Huijberts M, Apelqvist J, . High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50(1):18–25
   PubMed Web of Science ®Google Scholar
• . Van Battum P, Schaper N, Prompers L, . Differences in minor amputation rate in diabetic foot disease throughout Europe are in part explained by differences in disease severity at presentation. Diabet Med. 2011;28(2):199–205
   PubMed Web of Science ®Google Scholar
• . Snyder RJ, Kirsner RS, Warriner RA 3rd, Lavery LA, Hanft JR, Sheehan P. Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage. 2010;56( 4 suppl):S1–S24
   Google Scholar
• . Tecilazich F, Dinh T, Veves A. Treating diabetic ulcers. Expert Opin Pharmacother. 2011;12(4):593–606
   PubMed Web of Science ®Google Scholar
• . Urbancic—Rovan V. Causes of diabetic foot lesions. Lancet. 2005;366: 1675–1676
   PubMed Web of Science ®Google Scholar
• . Prompers L, Schaper N, Apelqvist J, . Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia. 2008;51(5):747–755
   PubMed Web of Science ®Google Scholar
• . Kosinski MA, Lipsky BA. Current medical management of diabetic foot infections. Expert Rev Anti Infect Ther. 2010;8(11): 1293–1305
   PubMed Web of Science ®Google Scholar
• . Karthikesalingam A, Holt PJ, Moxey P, Jones KG, Thompson MM, Hinchliffe RJ. A systematic review of scoring systems for diabetic foot ulcers. Diabet Med. 2010;27(5):544–549
   PubMed Web of Science ®Google Scholar
• . Monteiro—Soares M, Boyko EJ, Ribeiro J, Ribeiro I, Dinis—Ribeiro M. Risk stratification systems for diabetic foot ulcers: a systematic review. Diabetologia. 2011;54(5):1190–1199
   PubMed Web of Science ®Google Scholar
• . Armstrong DG, Laver LA, Harkless LB. Validation of a diabetic wound classification system: the contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. 1998;21(5):855–859
   PubMed Web of Science ®Google Scholar
• . Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev. 2004;20( suppl 1):S90–S95
   PubMed Web of Science ®Google Scholar
• . Lipsky BA, Berendt AR, Deery HG, ; Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004;39(7):885–910
   PubMed Web of Science ®Google Scholar
• . Lavery LA, Armstrong DG, Murdoch D P, Peters EJ, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis. 2007;44(4):562–565
   PubMed Web of Science ®Google Scholar
• . Armstrong DG, Liswood PJ, Todd WF. 1995 William J. Stickel Bronze Award. Prevalence of mixed infections in the diabetic pedal wound. A retrospective review of 112 infections. J Am Podiatr Med Assoc. 1995;85(10):533–537
   PubMed Web of Science ®Google Scholar
• . Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007;45(9): 2819–2828
   PubMed Web of Science ®Google Scholar
• . Lipsky BA, Itani KM, Weigelt JA, . The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. Int J Infect Dis. 2011;15(2):e140–e146
   Web of Science ®Google Scholar
• . Zubair M, Malik A, Ahmad J. Clinico-microbiological study and antimicrobial drug resistance profile of diabetic foot infections in North India. Foot (Edinb). 2011;21(1):6–14
   PubMedGoogle Scholar
• . Lipsky BA, Tabak Y P, Johannes RS, Vo L, Hyde L, Weigelt JA. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia. 2010;53(5):914–923
   PubMed Web of Science ®Google Scholar
• . Eleftheriadou I, Tentolouris N, Argiana V, Jude E, Boulton AJ. Methicillin-resistant Staphylococcus aureus in diabetic foot infections. Drugs. 2010;70(14):1785–1797
   PubMed Web of Science ®Google Scholar
• . Yates C, May K, Hale T, . Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care. 2009;32(10):1907–1909
   PubMed Web of Science ®Google Scholar
• . Stanaway S, Johnson D, Moulik P, Gill G. Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res Clin Pract. 2007;75(1):47–50
   PubMed Web of Science ®Google Scholar
• . Raja NS. Microbiology of diabetic foot infections in a teaching hospital in Malaysia: a retrospective study of 194 cases. J Microbiol Immunol Infect. 2007;40(1):39–44
   PubMedGoogle Scholar
• . Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry R. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care. 2006;29(8):1727–1732
   PubMed Web of Science ®Google Scholar
• . Weigelt JA. Diabetic foot infections: diagnosis and management. Surg Infect (Larchmt). 2010;11(3):295–298
   PubMed Web of Science ®Google Scholar
• . Stevens DL, Bisno AL, Chambers HF, ; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41(10): 1373–1406
   PubMed Web of Science ®Google Scholar
• . Butalia S, Palda VA, Sargeant RJ, Detsky AS, Mourad O. Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA. 2008;299(7):806–813
   PubMed Web of Science ®Google Scholar
• . Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. Clin Infect Dis. 2008;47(4):519–527
   PubMed Web of Science ®Google Scholar
• . Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010; 65( suppl 3):iii35–iii44
   PubMed Web of Science ®Google Scholar
• . Arnold J, Lucarelli M, Cutrona AF, DiDomenico LA, Karlock L. Toxic shock syndrome originating from the foot. J Foot Ankle Surg. 2001;40(6):411–413
   PubMedGoogle Scholar
• . Bader MS. Diabetic foot infection. Am Fam Physician. 2008;78(1):71–79
   PubMed Web of Science ®Google Scholar
• . Sella EJ. Current concepts review: diagnostic imaging of the diabetic foot. Foot Ankle Int. 2009;30(6):568–576
   PubMed Web of Science ®Google Scholar
• . Ramirez—Schrempp D, Dorfman DH, Baker WE, Liteplo AS. Ultrasound soft-tissue applications in the pediatric emergency department: to drain or not to drain? Pediatr Emerg Care. 2009;25(1):44–48
   PubMed Web of Science ®Google Scholar
• . Loredo R, Rahal A, Garcia G, Metter D. Imaging of the diabetic foot diagnostic dilemmas. Foot Ankle Spec. 2010;3(5):249–264
   PubMedGoogle Scholar
• . Palestro CJ, Love C. Nuclear medicine and diabetic foot infections. Semin Nucl Med. 2009;39(1):52–65
   PubMed Web of Science ®Google Scholar
• . Toledano TR, Fatone EA, Weis A, Cotten A, Beltran J. MRI evaluation of bone marrow changes in the diabetic foot: a practical approach. Semin Musculoskelet Radiol. 2011;15(3):257–268
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Gardner SE, Frantz RA, Saltzman CL, Hillis SL, Park H, Scherubel M. Diagnostic validity of three swab techniques for identifying chronic wound infection. Wound Repair Regen. 2006;14(5):548–557
   PubMed Web of Science ®Google Scholar
• . Aydin K, Isildak M, Karakaya J, Gürlek A. Change in amputation predictors in diabetic foot disease: effect of multidisciplinary approach. Endocrine. 2010;38(1):87–92
   PubMed Web of Science ®Google Scholar
• . Sanders LJ, Robbins JM, Edmonds ME. History of the team approach to amputation prevention: pioneers and milestones. J Vasc Surg. 2010;52( 3 suppl):3S–16S
   Web of Science ®Google Scholar
• . Bus SA, Valk GD, van Deursen RW, . Specific guidelines on footwear and offloading. Diabetes Metab Res Rev. 2008;24( suppl 1): S192–S193
   PubMed Web of Science ®Google Scholar
• . Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database Syst Rev. 2010;20(1):CD003556
   Google Scholar
• . Jude EB, Apelqvist J, Spraul M, Martini J; Silver Dressing Study Group. Prospective randomized controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in non-ischaemic diabetic foot ulcers. Diabet Med. 2007;24(3):280–288
   PubMed Web of Science ®Google Scholar
• . Jeffcoate WJ, Price PE, Phillips CJ, . Randomised controlled trial of the use of three dressing preparations in the management of chronic ulceration of the foot in diabetes. Health Technol Assess. 2009; 13(54):1–86
   PubMed Web of Science ®Google Scholar
• . Fan K, Tang J, Escandon J, Kirsner RS. State of the art in topical wound-healing products. Plast Reconstr Surg. 2011;127(suppl 1):44S–59S
   PubMed Web of Science ®Google Scholar
• . Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis. 2009;49(10):1541–1549
   PubMed Web of Science ®Google Scholar
• . Nelson SB. Management of diabetic foot infections in an era of increasing microbial resistance. Curr Infect Dis Rep. 2009;11(5):375–382
   PubMedGoogle Scholar
• . Kish TD, Chang MH, Fung HB. Treatment of skin and soft tissue infections in the elderly: a review. Am J Geriatr Pharmacother. 2010; 8(6):485–513
   PubMedGoogle Scholar
• . Lawrence KR, Golik M V, Davidson L. The role of primary care prescribers in the diagnosis and management of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Am J Ther. 2009;16(4):333–338
   PubMed Web of Science ®Google Scholar
• . Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007;44(6):777–784
   PubMed Web of Science ®Google Scholar
• . Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res Clin Pract. 2008;80(3):344–351
   PubMed Web of Science ®Google Scholar
• . Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992;117(5):390–398
   PubMed Web of Science ®Google Scholar
• . Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis. 2005;40(10):1429–1434
   PubMed Web of Science ®Google Scholar
• . Cenizal MJ, Skiest D, Luber S, . Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(7):2628–2630
   PubMed Web of Science ®Google Scholar
• . Hersh AL, Weintrub PS, Cabana MD. Antibiotic selection for purulent skin and soft-tissue infections in ambulatory care: a decision-analytic approach. Acad Pediatr. 2009;9(3):179–184
   PubMed Web of Science ®Google Scholar
• . Liu C, Bayer A, Cosgrove SE, . Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–e55
   PubMed Web of Science ®Google Scholar
• . Traunmüller F, Schintler M V, Spendel S, . Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents. 2010;36(1):84–86
   PubMed Web of Science ®Google Scholar
• . Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek DH. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother. 2007;60(4):819–823
   PubMed Web of Science ®Google Scholar
• . McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin Ther. 2007;29(3): 469–477
   PubMed Web of Science ®Google Scholar
• . Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract. 2009;63(3): 376–386
   PubMed Web of Science ®Google Scholar
• . Rayner CR, Baddour LM, Birmingham MC, Norden C, Meagher AK, Schentag JJ. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection. 2004;32(1):8–14
   PubMed Web of Science ®Google Scholar
• . Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis. 2006;42(5): 729–730
   PubMed Web of Science ®Google Scholar
• . Traunmüller F, Schintler MV, Metzler J, . Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother. 2010;65(6):1252–1257
   PubMed Web of Science ®Google Scholar
• . Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother. 2005;55(2):240–245
   PubMed Web of Science ®Google Scholar
• . Davis SL, McKinnon PS, Hall LM, . Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy. 2007;27(11):1611–1618
   PubMedGoogle Scholar
• . Krige JE, Lindfeld K, Friedrich L, . Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. Curr Med Res Opin. 2007;23(9):2147–2156
   PubMed Web of Science ®Google Scholar
• . Pertel PE, Eisenstein BI, Link AS, . The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract. 2009;63(3):368–375
   PubMed Web of Science ®Google Scholar
• . Petersen PJ, Ruzin A, Tuckman M, Jones CH. In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections. Diagn Microbiol Infect Dis. 2010;66(4):407–418
   PubMed Web of Science ®Google Scholar
• . Laohavaleeson S, Kuti JL, Nicolau D P. Telavancin: a novel lipogly-copeptide for serious gram-positive infections. Expert Opin Investig Drugs. 2007;16(3):347–357
   PubMed Web of Science ®Google Scholar
• . Stryjewski ME, Graham DR, Wilson SE, ; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46(11):1683–1693
   PubMed Web of Science ®Google Scholar
• . Barriere SL. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol. 2010;5(12):1765–1773
   PubMed Web of Science ®Google Scholar
• . Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2011;52(9):1156–1163
   PubMed Web of Science ®Google Scholar
• . Corey GR, Wilcox M, Talbot GH, . Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641–650
   PubMed Web of Science ®Google Scholar
• . Martin SJ, Zeigler DG. The use of fluoroquinolones in the treatment of skin infections. Expert Opin Pharmacother. 2004;5(2):237–246
   PubMed Web of Science ®Google Scholar
• . Saltoglu N, Dalkiran A, Tetiker T, . Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect. 2010; 16(8):1252–1257
   PubMed Web of Science ®Google Scholar
• . Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother. 2007;60(2):370–376
   PubMed Web of Science ®Google Scholar
• . Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet. 2005;366(9498):1695–1703
   PubMed Web of Science ®Google Scholar
• . Tascini C, Gemignani G, Palumbo F, . Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother. 2006;18(6):648–651
   PubMed Web of Science ®Google Scholar
• . Nicolau D P, Stein GE. Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics. J Am Podiatr Med Assoc. 2010;100(1):52–63
   PubMed Web of Science ®Google Scholar
• . Byren I, Peters EJ, Hoey C, Berendt A, Lipsky BA. Pharmacotherapy of diabetic foot osteomyelitis. Expert Opin Pharmacother. 2009; 10(18):3033–3047
   PubMed Web of Science ®Google Scholar
• . Schintler M V, Traunmüller F, Metzler J, . High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother. 2009;64(3):574–578
   PubMed Web of Science ®Google Scholar
• . Stevens DL, Smith LG, Bruss JB, . Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2000;44(12):3408–3413
   PubMed Web of Science ®Google Scholar
• . Embil JM, Rose G, Trepman E, . Oral antimicrobial therapy for diabetic foot osteomyelitis. Foot Ankle Int. 2006;27(10):771–779
   PubMed Web of Science ®Google Scholar
• . Cunha BA. Oral and i.v.-to-p.o. switch antibiotic therapy of hospitalized patients with serious infections. Scand J Infect Dis. 2008; 40(11–12):1004–1006
   PubMed Web of Science ®Google Scholar
• . Daver NG, Shelburne SA, Atmar RL, . Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect. 2007;54(6):539–544
   PubMed Web of Science ®Google Scholar
• . Euba G, Murillo O, Fernández—Sabé N, . Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother. 2009;53(6):2672–2676
   PubMed Web of Science ®Google Scholar
• . Kowalski TJ, Matsuda M, Sorenson MD, Gundrum JD, Agger WA. The effect of residual osteomyelitis at the resection margin in patients with surgically treated diabetic foot infection. J Foot Ankle Surg. 2011;50(2):171–175
   PubMed Web of Science ®Google Scholar
• . Berendt AR, Peters EJ, Bakker K, . Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab Res Rev. 2008;24:S145–S161
   PubMed Web of Science ®Google Scholar
• . Peters EJ, Lipsky BA, Berendt AR, . A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot. Diabetes Metab Res Rev. 2012;28( suppl 1):142–162
   PubMed Web of Science ®Google Scholar
• . Armstrong DG, Lavery LA; Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre randomized controlled trial. Lancet. 2005; 366(9498):1704–1710
   PubMed Web of Science ®Google Scholar
• . Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy utilizing vacuum-assisted closure to advanced moist wound therapy in the treatment of diabetic foot ulcers a multicenter randomized controlled trial. Diabetes Care. 2008; 31(4):631–636
   PubMed Web of Science ®Google Scholar
• . Game FL, Hinchliffe RJ, Apelqvist J, . A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2012;28( suppl 1):119–141
   PubMed Web of Science ®Google Scholar
• . Vig S, Dowsett C, Berg L, ; International Expert Panel on Negative Pressure Wound Therapy [NPWT-EP]. Evidence-based recommendations for the use of negative pressure wound therapy in chronic wounds: steps towards an international consensus. J Tissue Viability. 2011;20( suppl 1):S1–S18
   PubMed Web of Science ®Google Scholar